Peptide Specific Dendritic Cell
Leukemia, Acute Myelogenous (AML)
Zhujiang HospitalCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
685 Active assets in the Leukemia, Acute Myelogenous (AML) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gemtuzumab M.D. Anderson Cancer Center | Phase 4 | A |
Cytosin-Arabinosid Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | BBB |
AMSACRINE University Hospital, Toulouse | Phase 4 | BBB |
Posaconazole AstraZeneca | Phase 4 | BBB |
(+)-VINCRISTINE Janssen Research & Development, LLC | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Peptide Specific Dendritic Cell is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →